Previous 10 | Next 10 |
SELLAS Life Sciences ( SLS +4.4% ) bucks the broad market selloff, albeit on light volume, in reaction to preliminary data from an NCI-sponsored 13-subject Phase 2 clinical trial, VADIS , evaluating nelipepimut-S (NPS), combination with a granulocyte-macrophage colony-stimulating factor...
Biomerica (NASDAQ: BMRA ) +133% on advancement of rapid coronavirus test. More news on: Biomerica, Inc., IMV Inc., Vaxart, Inc., Stocks on the move, , Read more ...
NEW YORK, March 18, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indicat...
NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indicat...
SELLAS Life Sciences Announces Positive Readout for Leukemia Drug SELLAS Life Sciences' ( SLS ) stock shot up as the company reported positive results from its Phase 1/2 study of its Galinpepimut-S treatment for patients with acute myeloid leukemia. The trial demonstrated that the patients...
Anaplan (NYSE: PLAN ) -29% despite Q4 beat . More news on: Anaplan, Inc., Continental Resources, Inc., Nutanix, Inc., Stocks on the move, , Read more ...
Sellas Life Sciences ( SLS +45.4% ) skyrockets as much as 70% after unveiling positive results for its Phase 1/2 study of its Galinpepimut-S treatment for patients with acute myeloid leukemia. More news on: SELLAS Life Sciences Group, Inc., Healthcare stocks news, Stocks on the move, ...
SELLAS Life Sciences Group (NASDAQ: SLS ) +23% on positive follow-up phase 1/2 clinical data for Galinpepimut-S in acute myeloid leukemia. More news on: SELLAS Life Sciences Group, Inc., Alcon, Inc., Moderna, Inc., Stocks on the move, , Read more ...
- Final analysis shows statistically significant median overall survival of 21 months in patients who received GPS compared to previously reported 5.4 months in the control arm (p-value < 0.02) - - Data provides additional support for ongoing pivotal Phase 3 REGAL study of GPS i...
Gainers: Myomo (NYSEMKT: MYO ) +48% . More news on: Myomo, Inc., Enphase Energy, Inc., Altisource Asset Management Corporation, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
SELLAS Life Sciences Group Inc. Company Name:
SLS Stock Symbol:
NASDAQ Market:
SELLAS Life Sciences Group Inc. Website:
2024-07-19 10:10:00 ET July 19, 2024 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces today's roundup of stocks to watch in the Biotech, Cleantech Sectors. The newest biotech companies are involved in blood disorder treat...
- Acute Myeloid Leukemia (AML) is the Second Most Common Hematological Malignancy in Children Often Associated with Poorer Prognosis Compared to Other Pediatric Cancers – - This Recognition Marks SELLAS’ Second RPDD Following the Designation for ALL Received Last Month - -...
NEW YORK, July 08, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today ...